Primer

Yatsen Holding Limited Primer

Yatsen is a China-based beauty group that develops, acquires and markets a portfolio of color-cosmetics and skincare brands — flagship Perfect Diary alongside Little Ondine, Pink Bear, Galénic, DR.WU (mainland China) and Eve Lom — selling primarily direct-to-consumer through Tmall, Douyin, Xiaohongshu and other Chinese platforms. After a 2020 IPO blow-off and four years of restructuring losses, FY2025 was the inflection: revenue re-accelerated to +26.7% YoY, gross margin reached 78.2%, and Q4 2025 delivered the first quarterly net income since 2019. The stock has nevertheless given back roughly two-thirds of its value in the last six months (NYSE ADR), leaving a sub-1× sales tape on a balance sheet with net cash.

ADRs trade on NYSE in USD ($2.46 close on 2026-05-15); CNY equivalents above are converted at the latest available rate (1 CNY ≈ 0.14284 USD per data/company.json.fx_rates). Each ADR currently represents 20 Class A ordinary shares after the April-2024 ratio change.

Five-Year Price Tape (USD ADR)

The April-2024 ADR ratio change from 1:4 to 1:20 mechanically multiplied the per-ADR price by ~5×; the visible step-up in spring 2024 is therefore an accounting artifact, not a real return. Adjusting for this, holders of the IPO are down roughly 97% from the 2020 print. The June-2025 spike reflected enthusiasm around the Q1 2025 results and skincare premiumization; that move has fully retraced into the May-2026 print of $2.46.

Revenue And Operating Margin Trajectory (¥M / %)

Revenue fell from a ¥5.84B 2021 peak to a ¥3.39B trough in 2024 as Yatsen culled unprofitable color-cosmetics SKUs, exited heavy marketing on Perfect Diary and built out higher-margin skincare; the FY2025 reacceleration to ¥4,298M (+26.7%) was the first positive print in four years. Gross margin has expanded by ~14 points since 2020 as skincare mix has risen, and operating margin collapsed from −51% in FY2020 to roughly breakeven (−4.3%) in FY2025.

Business In One Page

Yatsen runs two reported product lines: color cosmetics (Perfect Diary, Little Ondine, Pink Bear) and skincare (Galénic, DR.WU mainland-China rights, Eve Lom, EANTiM). Founded in 2016 and IPO'd on NYSE in November 2020 with Hillhouse, Tiger and CMC as backers, the company was originally famed for a "KOL-driven, social-commerce" Perfect Diary playbook on Xiaohongshu and Douyin that delivered viral growth but produced unsustainable customer-acquisition costs once the platforms tightened algorithms in 2021. Distribution is essentially 100% direct: Tmall flagships, JD, Douyin live-streaming, Xiaohongshu, WeChat mini-programs and a thin offline experience-store footprint, with limited international distribution into the rest of Asia and Europe (per the company profile at ir.yatsenglobal.com).

The strategic pivot has been mix-shift from mass color cosmetics to clinical / "science-backed" skincare, which now carries the higher gross margins driving the consolidated 78.2% FY2025 print. Eve Lom (UK premium skincare, acquired 2020 for ~$216M) and Galénic (Pierre Fabre's French dermo-cosmetic brand, acquired 2022) anchor the international/scientific skincare portfolio; DR.WU's mainland China business (acquired 2021) anchors clinical-skincare distribution. The company emphasizes a ~$100M cumulative R&D investment with its own labs and a 2023 Perfect Diary rebrand aimed at Gen-Z and millennial consumers. FY2025 R&D was ¥137M (3.2% of sales), among the highest in Chinese color-cosmetics peers.

Valuation And Balance Sheet Snapshot

At the May-2026 share price the market values Yatsen at roughly ¥1.6B in equity, against ¥1,011M of cash and ~¥177M of debt at year-end FY2025 (net cash ¥835M, or roughly $119M); enterprise value is therefore well under 1× trailing sales and is closer to 0.4× on EV/Sales. Reported P/E is not meaningful given GAAP losses, but the company turned positive on a non-GAAP basis in 2024 and printed positive GAAP net income of ¥8M in Q4 2025. Tangible book value per share is ¥24.9, leaving the share trading near 0.7× tangible book in CNY-equivalent terms. The market is clearly framing YSG as a chronic loss-maker entitled to a "China consumer ADR" discount despite the turnaround — second-derivative tape, not first-derivative fundamentals.

What Changed Recently

• Q4 2025 results (released 2026-03-02) delivered ¥1,379M revenue (+20% YoY) and the first quarterly GAAP net income (¥8M) since Yatsen's pre-IPO years, with gross margin at 77.7%. Full-year FY2025 revenue of ¥4,298M was +26.7% and the operating loss narrowed by ~¥639M to (¥186M). (source: data/financials/income.json, income_quarterly.json)
• Q1 2026 guidance: net revenues of ¥958.6M to ¥1,080M, representing +15% to +30% YoY growth — per the company's 2026-03-02 release (marketscreener.com 2026-03-02, sahmcapital.com 2026-03-02).
• $120M convertible-note placement signed in March 2026 (announced 2026-03-11, marketscreener.com). Funds will support skincare brand-building and working capital; ratio_buyback_yield was already 4.1% in FY2025, so the convert dilution sits alongside continued buybacks.
• Q3 2025 highlight: gross margin reached 78.2% with revenue up ~47.5% YoY, narrowing GAAP net loss by 41.9% to ¥70.4M; described in third-party SWOT write-ups as evidence the premiumization shift is working (dcfmodeling.com SWOT — Apr-2026 update).
• 2025 Annual Report on Form 20-F filed 2026-04-29 (ir.yatsenglobal.com/2026-04-29-Yatsen-Filed-2025-Annual-Report-on-Form-20-F), the first 20-F after the convert deal and Q4 inflection.
• Sell-side framing shifted to "fairly valued" after the early-2026 spike (Seeking Alpha Mar-04 piece downgrading to Hold), citing turnaround progress alongside geopolitical/delisting risk.

Risks And Watchpoints

• China discretionary-beauty demand is fragile. FY2024 revenue actually fell again (−0.6% vs FY2023) before the FY2025 rebound; a single soft 618 / Singles' Day cycle could re-rate the growth story quickly.
• Free cash flow remains negative. Even in the much-improved FY2025, operating cash flow was −¥95M and FCF was −¥137M; the cash balance dropped from ¥1,357M to ¥1,011M over the year (cash_flow.json). The March-2026 convert is partly a backstop, but cash burn has continued for eight years.
• Persistent buybacks and SBC mask dilution. FY2025 SBC was ¥59M and the company bought back ¥111M of stock against ~93M ADRs outstanding; ordinary-share count is ~1.88B and weighted-average diluted shares are still drifting. Convertible issuance will add to potential dilution above the conversion price.
• HFCAA / ADR delisting overhang. As a China-domiciled NYSE-listed issuer with VIE structure, YSG carries auditor-access and forced-delisting risk that has weighed on the multiple for the entire peer group; Simply Wall St and Seeking Alpha both flag geopolitical risk in recent notes.
• Brand concentration and category competition. Perfect Diary's market position has compressed since 2021 versus local rivals (Proya, Mao Geping, S'Young's Magic) and resurgent international skincare lines; the SKU rationalization that improved margins also leaves a thinner color-cosmetics product wall.
• Liquidity is genuinely thin. Average 20-day USD ADV is ~$304K (data/tech/liquidity.json), 60-day ~$455K; institutional position-building requires patient block execution and the "specialist only" verdict is appropriate.

What To Verify Next

• Q1 2026 release (expected 2026-05-18 per stockinvest.us cadence): did revenue land at the upper or lower end of the ¥959–1,080M guide, and did gross margin hold the ~78% post-Singles' Day window?
• Skincare vs. color-cosmetics segment split disclosed in the 2025 Form 20-F (filed 2026-04-29) — confirm the proportion of revenue and gross profit attributable to Galénic / Eve Lom / DR.WU vs. Perfect Diary / Little Ondine / Pink Bear.
• Use of proceeds on the $120M convertible — terms, strike, conversion ratio and whether management commits to a deleveraging/expansion plan or simply replenishes the FY2026 working-capital base.
• Operating cash-flow inflection: FY2025 was the first year with materially narrowed operating losses but FCF was still negative; a clean OCF-positive quarter would change the cost-of-capital story.
• Insider/sponsor ownership trend — Hillhouse, Tiger and other pre-IPO holders' current position vs. 2025 (verify via 13F/Form 4 trail at MarketBeat or hedgefollow.com), and whether any new institutional accumulation appeared on the late-2025 rally.